Dynasty Fine Wines’s White Wine Revenue Transcends Red Wine for The First Time in The First Half of 2022 ACN Newswire

Dynasty Fine Wines’s White Wine Revenue Transcends Red Wine for The First Time in The First Half of 2022

August 27, 2022
HONG KONG, Aug 26, 2022 - (ACN Newswire via SEAPRWire.com) - Dynasty Fine Wines Group Limited ("Dynasty" or the "Group") (Stock Code: 00828), a premier grape winemaker in China, today announced its unaudited interim results for the six months ended 30 June 2022.During the period, the resurgence of COVID cases in various cities in China caused the imposing of control and lockdown measures in consuming places and also led to adverse impact on consumer sentiment. As a result, in the first half of 2022, the Group's revenue decreased by 44% to HK$101 million, compared to the same period last year, whereas profit attributable to owners of the Company dropped by 45% to HK$10.7 million. However, gross profit margin increased from 38% in the first half of 2021 to 40% during the period.With consumers' growing interest in white wine products of the Group, especially in coastal regions of China, revenue of white wine products transcended red wines products for the first time in the first half of 2022, as the Group's major revenue contributor, accounted for approximately 52% (2021 1H: 41%) of the Group's revenue for the period. Red wines revenue accounted for 45% (2021 1H: 58%). During the period, the gross margin of white wine products and red wine products were 44% and 35% respectively (2021 1H: 35% and 39% respectively).The Group produces a wide range of more than 100 wine products under the "Dynasty" brand. It has been actively pursuing innovation, embracing the "5+4+N" product strategy. The Group's 5 key series of products comprise the air dry series, seven-year reserve series, merlot series, classic series and best-selling series, which cover fully the price range of mainstream markets, whereas the 4 advantageous product categories include dry red wines, dry white wines, brandy and sparkling wines, which enlarge vertical market shares for the Group. Furthermore, the Group boasts the development of "N" kinds of customized products to meet the diversified needs of Chinese consumers. During the period, the Group launched a new round of upgraded products, the innovative 373ml and 180ml Dynasty dry red and semi-dry white series. The new sizes coming with screw caps offer greater convenience to enjoy and young and chic styles that target the young consumer market. The 180ml wine comes in boxes of six, giving young people another choice of drinks than beers in gatherings. As for the 373ml size, with online-to-offline (O2O) platform support, consumers can scan the product QR code and get rewards. Moreover, the Group has created a gift box during the period for the collection of "Pleasant Color" wines which targets the young consumer market as well. The gift option is ideal for gatherings with family and friends and festive celebrations. New product launch and product upgrade are not only promoting interaction between consumers and the Group's brand, but also ultimately enable Dynasty's products to reach wider consumer groups.In addition, the Group also sold chateau wines imported from France and other foreign branded wines in China through the Group's existing distribution network. In that way, the Group introduced classic "old world" and "new world" varietals to cater for the consumer group preferring the taste of foreign premium wines.During the year, the Group's e-commerce team started to operate online stores on such traditional e-commerce platforms as JD.com, Tmall and Pinduoduo. Moreover, innovations were achieved across its brands, product categories, business systems, operation procedures and models via new retail platforms including Weibo, RED (Xiaohongshu app), Kuai (Kuaishou app) and TikTok (Douyin app), which replaced the cooperation with distributors. The e-commerce team has also actively cultivated e-commerce live broadcasting talents to further expand the Group's sales channels so as to build up a new customer base.The Group held its tasting and business events this February and June, during which the Group actively promoted its latest product mix that covered all product lines, and received enthusiastic market response. Close to the end of the first half of the year, the pandemic has subsided in most regions of China, and the business and sales of the Group has a gradual recovery to normal. Against this backdrop, the Group will continue its reform in sales and marketing. Following the relaxation of COVID control and lockdown measures, the Group will forge ahead the mass-scale marketing campaign showcasing 20,000 shops, hosting 1,000 wine tasting events and organising 100 plant visits, so as to keep developing and enhancing its point-of-sale network.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, "Looking ahead to the second half of 2022, Dynasty will further strengthen presence in Ningxia and Xinjiang to secure the supply of quality grapes and grape juice, and plan for the development of local production bases of grape juice in these regions in the long term. In addition, following the gradual containment of the COVID situation and relaxation of control and lockdown measures at the end of the second quarter of 2022, as well as the policy support for the recovery of economy, the Board currently remains cautiously optimistic on the business in the second half of 2022. The Group will continue to be well prepared to tackle the uncertainties associated with the pandemic, proactively develop the market, enhance product quality and boost sales volume." Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
China Bluechem Sees Record-High Interim Profit From Recurring Operation Since 2013 ACN Newswire

China Bluechem Sees Record-High Interim Profit From Recurring Operation Since 2013

August 26, 2022
HONG KONG, Aug 26, 2022 - (ACN Newswire via SEAPRWire.com) - China BlueChemical Ltd. ("China BlueChem" or the "Company," stock code: 3983), the largest state-owned chemical fertiliser producer and the leading methanol producer in China, announced its unaudited interim results for the six months ended 30 June 2022. Financial Highlights (Unaudited):For the Six Months Ended 30 June(RMB Million) 2022 2021 ChangeRevenue 7,371 6,110 +20.6%Gross Profit 1,408 1,285 +9.6%Net Profit Attributable to Owners of the Company 937 1,246 -24.8%Net Profit Attributable to Owners of the Company (excluding a one-off item) 937 868 +8.0%Basic Earnings per Share (RMB) 0.20 0.27 -25.9%In the first half of the year, the Company realized a revenue of RMB 7,371 million, a surge of 20.6% over the corresponding period last year. Net profit attributable to owners of the Company amounted to RMB 937 million. In comparison with net profit attributable to owners of the Company after excluding a one-off item relating to Hualu Yangpoquan project for the first half of last year, which was RMB 868 million, the interim profit of this year is not only 8.0% higher than that of 2021, but also breaks the record of interim profits since 2013.The Company consistently upholds the philosophy of green and sustainable development. In the first half of the year, the Company reduced 34 thousand tonnes of carbon emissions. It was the eleventh consecutive year that the Company had been awarded the Benchmark Enterprise of Leading Energy Efficiency in the Methanol Industry by China Petroleum and Chemical Industry Federation. Against the backdrop of "dual carbon" goals, the Company actively conducted research activities on the comprehensive utilisation of high carbon dioxide bearing natural gas and entered into a joint development agreement with BASF and Wuhuan Engineering, positioning itself as the first mover in the large-scale carbon dioxide utilisation.Mr. HOU Xiaofeng, CEO and President of China BlueChem said, "In the first half of 2022, the Company implemented superb financial management without compromising social responsibility. It is encouraging that we reduced 34 thousand tonnes of carbon emissions and achieved a record high interim profit since 2013 after excluding the effect of one-off items in results in the comparison. As the largest state-owned chemical fertiliser producer and the leading methanol producer in China, China BlueChem firmly adheres to the principles of guarding against the pandemic, keeping the economy steady and achieving safe development. We have been fully boosting sales and marketing, enhancing production management, consistently controlling costs and raising efficiencies, and exploring price premium of our product brands."In the production perspective, the Fudao Phase I and Fudao Phase II urea plants completed their respective annual plant overhauls as scheduled with the required quality. The Hainan Phase I and Hainan Phase II methanol plants recorded the highest output volume for the corresponding period in the recent 5 years. In the first half of 2022, the Company produced 909 thousand tonnes of urea, 773 thousand tonnes of methanol, 522 thousand tonnes of phosphate fertilisers and compound fertilisers, and 5 thousand tonnes of polyformaldehyde (POM).With regards to sales and marketing, the Company rode on the rising trend in prices of chemical fertilisers and chemical products to become the market leader in terms of methanol price and fully reap the market through strategic pricing of chemical fertilisers. It also enhanced the quality and scale of the self-operated business to realise its contribution to the sales value of the Company. In the first half of 2022, the Company sold 949 thousand tonnes of urea, 722 thousand tonnes of methanol, 515 thousand tonnes of phosphate fertilisers and compound fertilisers, and 3,484 tonnes of POM. Under the Company's continued efforts in optimising the product portfolio, the sales volume of value-added products hit a record high, making a year-on-year increase of 73 thousand tonnes.Regarding the progress of the Company's key projects, the construction and pre-production preparation works of the acrylonitrile project were smoothly underway and the milestone targets were essentially achieved. The Company has been actively working on the acquisition of Orient Petrochemical and made substantive progress on the transfer of equity interests in DYK Chemical and CNOOC Tianye. As for the industry outlook in the latter half of the year, the domestic demand is traditionally low in the third quarter, so the domestic urea market may possibly face significant price mark-downs, whereas there is a possibility that the urea market may bottom out and rally in the fourth quarter, causing concerns on the supply of natural gas and the scale of off-season stockings. Given the reduction in prices of main raw materials, the supply of phosphate fertilisers is expected to loosen up in the domestic market, which will exert a greater pressure on the domestic sales, and the prices will thereby start to go down with fluctuations along with the costs. As for methanol, the excessive supply over demand will persist. Dampened by deteriorating macro views, the market is expected to be weaker and will experience rocky adjustments. The POM market is expected to see a more adequate supply and the key concern will be whether the downstream demand can be restored. In respect of the Company's development in the latter half of the year, the Company will strictly implement prevention and control of normalised epidemic, and endeavour to achieve safe and stable operation for all production plants. It will strengthen the monitoring of equipment with potential dangers, reinforce the management, maintenance and overhauling of outdated equipment, and address bottleneck issues with consolidated technical skills. The Company will also further enhance its acumen in assessing the market, promote brand building and strive to gain a greater say in the market. Looking to the future, Mr. HOU said, "China BlueChem has full confidence over its future. We will push the acrylonitrile project forward to ensure successful trial operation and get its production and sales well prepared. At the same time, we will speed up the construction of the petrochemical wharf with a throughput of 20 thousand tonnes in Xingang Zone of Basuo Port in Hainan Province. Furthermore, we will actively proceed with the acquisition of Orient Petrochemical, and complete the transfer of equity interests in DYK Chemical and CNOOC Tianye in a steady manner. Research activities on the technology of carbon-rich natural gas utilisation and the cooperation with BASF and Wuhuan Engineering will be accelerated, with the aim to facilitate the Company with more advanced technology of carbon fixation to promote green and low-carbon development." Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82% ACN Newswire

New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%

August 19, 2022
HANGZHOU, Aug 19, 2022 - (ACN Newswire via SEAPRWire.com) - New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today.Based on the financial information before the audit as of June 30, 2022, New Horizon Health achieved total revenue of RMB226 million in the first half of 2022, an increase of 414% over the same period in 2021; achieved a gross profit of RMB185 million, an increase of 650% over the same period in 2021; gross profit margin climbed to 82.0% from 56.2% in the first half of 2021. The Company's adjusted net loss for the half-year was RMB106 million and the adjusted net loss rate(1) narrowed significantly from 221% to 47%; the ratio of expenses to sales(1) dropped significantly from 161% to 86%, and the ratio of management expense to sales(1) dropped significantly from 80% to 23%. The Company's total cash, including time deposits, cash, and cash equivalents, amounted to RMB1.65 billion.The Company announced its cervical cancer screening product, CerviClear(TM), which had been launched in a large-scale prospective multi-center registered clinical trial in June 2022. CerviClear(TM) is the world's first HPV cervical cancer screening product that provides painless and non-invasive urine self-sampling at home, covering a comprehensive range of 14 high-risk HPV viruses. The clinical trial for LiverClear(TM) is progressing well and is expected to be launched in the fourth quarter of 2022 or the first quarter of 2023. As of June 30, 2022, the Company's R&D expenses(1) were RMB39.4 million, an increase of 111% over the same period in 2021."The results of the interim report were not easy to get. New Horizon Health's team is faithful to its promise that it is able to do what it says and do what it does. The Company's revenue in the first half of the year has exceeded last year's full-year revenue. The performance growth is mainly attributed to the increase in revenue and gross profit of ColoClear and Pupu Tube, as well as the listing of UU Tube. The underlying logic of the high growth and high gross profit of the three products is that more and more people with high risk are accelerating the change of concept, attaching importance to the risk prevention and control of high incidence cancer in personal and family health management, recognizing the important value of cancer early screening product compliance and willing to pay for it", the Chairman and CEO of New Horizon Health, YeQing ZHU, said, "Cancer early screening products are both serious medical and consumer products, and the huge market opportunity is backed by the high barrier of research and development and compliance as well as the high investment in market education. The necessary condition for the approval of cancer early screening products under New Horizon Health is solid prospective large-scale multi-center registration clinical validation, which is the strong barrier of our diversified business strategy and the foundation of user trust."Normalization of COVID-19 epidemic accelerates the market education process for early screening at home: ColoClear and Pupu Tube continue to see 3-digit revenue growthColoClear achieved revenue of RMB73.6 million in the first half of 2022, representing an increase of 419% over the same period in 2021. The shipment volume in the first half of the year was approximately 294,600 kits, representing an increase of 143% over the same period in 2021. The increase in revenue of ColoClear was mainly due to the increase in volume sold and recognized as revenue and the increase in average recognition unit price.China's first at-home self-testing FIT test product, Pupu Tube, achieved revenue of RMB68.5 million in the first half of 2022, an increase of 132% over the same period in 2021; and achieved shipment of 2,929,700 units, an increase of 54% over the same period in 2021. The increase in revenue recognized by Pupu Tube was mainly due to the increase in sales volume and the increase in the average unit price (including the increase in the unit price of direct-to-consumer pipeline and the increase in the unit price of health check centers).Other than New Horizon Health, no domestic player has yet announced the launch of a large-scale prospective multi-center registration clinical trial for colorectal cancer screening. ColoClear is the only product approved by the National Medical Products Administration of China for screening cancer. Pupu Tube is the only approved product for at-home self-testing of FIT in China. In February 2022, ColoClear's multi-target stool FIT-DNA technology was recommended by the latest version of the Cancer Foundation of China's "China Integrated Cancer Treatment Guidelines", making it the only molecular early screening technology in China to be included in all national guidelines for colorectal cancer prevention and treatment.In the first half of 2022, the policy of early screening of cancer at home was intensively favorable. The "14th Five-Year Medical Equipment Industry Development Plan ", the "14th Five-Year National Health Plan " and the "14th Five-Year Bio-economic Development Plan " all focus on "early screening and health management of key diseases" such as cancer and in vitro diagnosis in home scenes. The normalization of the detection of COVID-19 epidemic has accelerated the public's awareness of home screening and healthy "symptom-free" people.The only consumer self-test for H. pylori testing: $83.5 million in half-year sales revenue for UU TubeAs of June 30, 2022, the sales revenue of UU Tube since its listing on January 18, 2022, was RMB83.5 million.On December 31, 2021, UU Tube was approved for registration as a Class III medical device by the National Medical Products Administration of China and is the only product in China that is suitable for "consumer self-testing" for H. pylori detection, for which we have the exclusive patented design of the "pregnancy test stick" which is an integrated design for sampling and testing.Data show that more than half of the users of UU Tube are women, nearly 50% are aged 31-40, and people aged 24-30 and 40-50 are also the main users. Jiangsu, Guangdong and Zhejiang have ranked the top three provinces in terms of the number of UU Tube users, and household users are more concerned about the detection and prevention of H. pylori.The prevention and control of H. pylori is a major focus of the science of gastric cancer prevention and has been receiving widespread attention from the media and the public. Data show that in the first half of 2022, the epidemic prevention and control led to a significant decline in the measurement of H. pylori breath tests in hospitals and health checkups, while the number of online and offline gastroenterology consultations continued to rise during the same period, effectively boosting consumer demand for home testing of H. pylori and strongly supporting the rapid promotion of H. pylori.Diversification of 2C quality pipes in tandem: ColoClear, Pupu Tube and UU Tube have excellent profitability performanceIn the first half of 2022, all the three marketed products demonstrated excellent profitability, with the gross margins of ColoClear and Pupu Tube continuing to increase significantly compared to the same period in 2021. As of June 30, 2022, the gross margin of ColoClear reached 75.7%, the gross margin of Pupu Tube reached 80.0% and the gross margin of UU Tube reached 90.0%. Compared to the same period in 2021, the gross margins of ColoClear and Pupu Tube were 56.6% and 59.0%, respectively.The Company's sales volume of the core pipeline increased steadily in the first half of 2022, and the new pipeline continued to make efforts to take advantage of the favorable macro and micro home inspection policies in the first half of the year with "Resilient" marketing and firmly implementation. The high gross margin of the three products benefited from the Company's continuous and in-depth diversified business strategy, which optimized the pipeline mix for product sales, increased the revenue of single test for direct-to-consumer pipelines and brought about scale production through operational leverage benefits, which further reduced the operating cost of a single test.In the first half of the year, the Company has been making progress online and offline, both inside and outside the hospital. As of June 30, 2022, the Company has completed access and sales to over 800 hospitals in the first half of the year. During the "618" period, New Horizon Health continued to be the champion in sales of JD in three categories: medical devices, consumer medical and genetic testing. UU Tube won the top selling category of Tmall test paper. The Company's total sales in JD and Tmall exceeded RMB40 million, representing a 400% increase in total sales compared to the same period in 2021, and a 300% increase in sales of ColoClear YoY.Based on the mainland market, start international marketing: ColoClear debuted in Hong Kong and will advance to Southeast Asia in phases2022 is a milestone year for the internationalization of New Horizon Health. On May 23rd, the Company and Prenetics (Nasdaq: PRE) made a joint announcement that the two parties have launched in-depth cooperation to fully integrate the quality resources in market and pipeline development and product and service operation, and jointly promote the market coverage of ColoClear in Hong Kong, Macau and Taiwan, China, and explore the market opportunities in countries or regions in Southeast Asian at the same time. On June 8, ColoClear by Circle was officially launched in Hong Kong with an official price of HK$3,000. During the cooperation period, ColoClear is the colorectal cancer early screening product that Prenetics has exclusively partnered with.At the same time as ColoClear's debut in the Hong Kong market, New Horizon Health announced the establishment of the Company's first international R&D center in the Hong Kong Science and Technology Parks to attract global talent and focus on multi-omics cancer screening technology innovation and product development, including NGS, and to drive overseas commercialization and synchronized global clinical trials.About New Horizon HealthFounded in 2015, New Horizon Health is a pioneer and leader in China's cancer screening market, focusing on early home screening of high-incidence cancers, aiming to promote innovation in cancer screening technology and accelerate the popularity of cancer screening technology in China. On February 18, 2021, New Horizon Health was successfully listed on the SEHK with stock code 6606.HK, which became "the first listed Chinese cancer early screening company".New Horizon Health has three marketed products. ColoClear, Pupu Tube and UU Tube have all been approved by the National Medical Products Administration of China and are officially commercialized. ColoClear is the only cancer screening product approved by the National Medical Products Administration of China for people aged 40-74 who are at high risk of colorectal cancer. UU Tube is the only consumer self-test product for Helicobacter pylori approved by the National Medical Products Administration of China. Pupu Tube is the first FIT at-home self-test device approved in China. In addition, the Company has three pipelines of products in development for liver cancer (LiverClear), cervical cancer (CerviClear ) and nasopharyngeal cancer screening. The Company has global rights to all of its marketed and pipeline products. New Horizon Health works extensively with hundreds of hospitals, health check-ups, insurance companies, pharmacies and online channels. The Company has a class 100,000 clean production workshop that meets ISO13485 and ISO9001 international certification standards. The third parties medical testing laboratories in Beijing, Hangzhou and Guangzhou have been certified by international quality standards and the local health care commission and issued licenses to practice, with an annual testing capacity of 2 million people.(1) Excluding equity incentive-related expenses Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
TTI Delivers Strong 2022 First Half Results ACN Newswire

TTI Delivers Strong 2022 First Half Results

August 10, 2022
HONG KONG, Aug 10, 2022 - (ACN Newswire via SEAPRWire.com) - Global leader in cordless Professional Tools, DIY Tools, and Outdoor Power Equipment, Techtronic Industries Co. Ltd. ("TTI" or the "Group") (stock code: 669, ADR symbol: TTNDY) is pleased to announce its results for the six months ended June 30, 2022. The Group delivered strong results for the first half of 2022, outpacing the market and growing sales by 10.0% to US$7.0 billion. In local currency, sales grew 12.1%. Combined with the 2021 first half sales growth of 52%, TTI has increased sales by 67% over this two-year period. Gross margin improved for the 14th consecutive first half expanding 50 bps to 39.1%. EBIT increased 10.7% to US$633 million, net profit rose 10.4% to US$578 million, and earnings per share increased 10.4% to approximately US31.59 cents per share.-- Our flagship MILWAUKEE business significantly outgrew the market, delivering 25.8% sales growth-- Gross margin improved for the 14th consecutive first half to 39.1%-- Net profit growth of 10.4% to US$578 millionFinancial Performance Highlights for 1H 2022 2022* 2021 US$' US$' million million ChangeRevenue 7,034 6,394 +10.0%Gross profit margin 39.1% 38.6% +50 bpsEBIT 633 572 +10.7%Profit attributable to Owners of the Company 578 524 +10.4%Basic earnings per share (US cents) 31.59 28.62 +10.4%Interim dividend per share (approx. US cents) 12.23 10.94 +11.8%*For the six-month period ended June 30, 2022The Group is delighted that all of its geographic regions delivered solid sales growth in the first half. Rest of World featuring Australia and Asia delivered outstanding 23.0% growth in local currency. Europe grew 14.1% in local currency and North America grew 10.5% in local currency.TTI's Power Equipment business delivered a very strong first half, while Floorcare contracted due to slowing demand and customer destocking. Now the global leader in professional cordless, TTI's flagship MILWAUKEE business continued to flourish with 25.8% local currency sales growth in the first half. This business now accounts for a major part of the company sales with an accretive gross margin.Mr. Horst Pudwill, Chairman of TTI, said, "Our world-class team is well prepared to manage the business through challenging macroeconomic environments and continue to deliver above market results. We are well positioned to strengthen our leadership position in the months and years to come." Mr. Joseph Galli, CEO of TTI, commented, "Our outstanding first half performance is the result of our ongoing new product flow and our market leadership position. We will continue to execute our proven strategy of investing in demonstrably better, technologically advanced new products to drive our growth." About TTI Founded in 1985 and listed on the Stock Exchange of Hong Kong Limited in 1990, TTI is a world leader in cordless technology spanning Power Tools, Outdoor Power Equipment, Floorcare and Cleaning Products for the consumer, professional, and industrial users in the home, construction, maintenance, industrial and infrastructure industries. The Company has a foundation built on four strategic drivers - Powerful Brands, Innovative Products, Exceptional People and Operational Excellence - reflecting a long-term expansive vision to advance cordless technology. The global growth strategy of the relentless pursuit of product innovation has brought TTI to the forefront of its industries. TTI's powerful brand portfolio includes MILWAUKEE, AEG and RYOBI power tools, accessories and hand tools, RYOBI and HOMELITE outdoor products, EMPIRE layout and measuring products, and HOOVER, ORECK, VAX and DIRT DEVIL floorcare cleaning products and solutions.TTI is one of the constituent stocks of the Hang Seng Index, FTSE RAFI(TM) All-World 3000 Index, FTSE4Good Developed Index and MSCI ACWI Index. For more information, please visit www.ttigroup.com.All trademarks listed other than AEG and RYOBI are owned by the Group. AEG is a registered trademark of AB Electrolux (publ.), and is used under license. RYOBI is a registered trademark of Ryobi Limited, and is used under license. For enquiries:Techtronic Industries Co. Ltd.Main ContactTTI Investor RelationsTel: +1 (954) 541 9660Email: ir@ttihq.comAsia/PacificTTI Investor RelationsTel: +(852) 2402 6888Email: ir@tti.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Toyota Announces Sales, Production, and Export Results for the First Half of 2022 JCN Newswire

Toyota Announces Sales, Production, and Export Results for the First Half of 2022

July 28, 2022
Toyota City, Japan, Jul 28, 2022 - (JCN Newswire via SEAPRWire.com) - Toyota Motor Corporation (TMC) announces its sales, production, and export results for June 2022 as well as the cumulative total from January to June, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd.Highlights:In the first half of 2022, both sales and production fell below the previous year's level due to impact from the global spread of COVID-19 as well as semiconductor shortages.However, production outside of Japan exceeded that of the previous year due to increased capacity and production optimization in China and a rebound from a slump caused by the impact of COVID-19 in various countries in the previous year, particularly in Asia.The situation remains difficult to predict due to the impact of semiconductor shortages and the spread of COVID-19, and there is the possibility that there will be a downturn in the production plan. However, we will continue to carefully monitor the supply of parts and minimize sudden decreases in production as much as possible while making every effort to deliver as many vehicles as possible to our customers at the earliest possible date.For the full report, visit https://global.toyota/en/company/profile/production-sales-figures/202206.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More